ramipril actavis 10mg tableta
actavis group ptc ehf., hafnarfjördur array - 9374 ramipril - tableta - 10mg - ramipril
ramipril actavis 2,5mg tableta
actavis group ptc ehf., hafnarfjördur array - 9374 ramipril - tableta - 2,5mg - ramipril
ramipril actavis 5mg tableta
actavis group ptc ehf., hafnarfjördur array - 9374 ramipril - tableta - 5mg - ramipril
ramipril h actavis 2,5mg/12,5mg tableta
actavis group ptc ehf., hafnarfjördur array - 9374 ramipril; 728 hydrochlorothiazid - tableta - 2,5mg/12,5mg - ramipril a diuretika
ramipril h actavis 5mg/25mg tableta
actavis group ptc ehf., hafnarfjördur array - 9374 ramipril; 728 hydrochlorothiazid - tableta - 5mg/25mg - ramipril a diuretika
desloratadine actavis
actavis group ptc ehf - desloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminika pro systémové použití, - léčba alergické rinitidy a kopřivky.
pioglitazone actavis
actavis group ptc ehf - pioglitazon hydrochlorid - diabetes mellitus, typ 2 - léky užívané při diabetu - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. po zahájení léčby pioglitazonem u pacientů by měly být přezkoumány po 3 až 6 měsíců k posouzení přiměřenosti odpovědi na léčbu (e. snížení hba1c). u pacientů, kteří nedokážou ukázat adekvátní odpověď, že pioglitazon by měla být přerušena. ve světle potenciální riziko dlouhodobé léčby, lékař by se měl potvrdit v následujících rutinní recenze, že přínos pioglitazonu je zachována (viz bod 4.
clopidogrel actavis 75mg potahovaná tableta
actavis group ptc ehf., hafnarfjördur array - 3239 klopidogrel-sulfÁt - potahovaná tableta - 75mg - klopidogrel
atomoxetin actavis 10mg tvrdá tobolka
actavis group ptc ehf., hafnarfjördur array - 17338 atomoxetin-hydrochlorid - tvrdá tobolka - 10mg - atomoxetin
atomoxetin actavis 100mg tvrdá tobolka
actavis group ptc ehf., hafnarfjördur array - 17338 atomoxetin-hydrochlorid - tvrdá tobolka - 100mg - atomoxetin